Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $240.3 million.

  • Phathom Pharmaceuticals' Liabilities and Shareholders Equity fell 3791.69% to $240.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 2124.42%. This contributed to the annual value of $378.3 million for FY2024, which is 858.4% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Liabilities and Shareholders Equity stood at $240.3 million, which was down 3791.69% from $250.2 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $413.8 million during Q4 2023, with a 5-year trough of $144.0 million in Q1 2023.
  • Its 4-year average for Liabilities and Shareholders Equity is $267.7 million, with a median of $250.2 million in 2025.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Liabilities and Shareholders Equity surged by 15110.25% in 2023 and then tumbled by 3791.69% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Liabilities and Shareholders Equity stood at $164.8 million in 2022, then skyrocketed by 151.1% to $413.8 million in 2023, then fell by 8.58% to $378.3 million in 2024, then tumbled by 36.48% to $240.3 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $240.3 million for Q3 2025, versus $250.2 million for Q2 2025 and $294.2 million for Q1 2025.